
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is expected to have strong potential in the retinal disease market with promising early clinical results for its anti-VEGF therapy, TH103, aimed at addressing the high unmet need for durability of treatment in wet AMD patients. With a focus on patient impact and ethical practices, the company has garnered support from key opinion leaders and analysts project a positive future performance with a current target price of $25. However, there are inherent risks associated with its early stage of development and competition in the market. It is expected to release preliminary data in the first half of 2027.
Bears say
Kalaris Therapeutics is poised to gain a significant market share in the wet AMD market with their potentially superior TH103 drug, which offers longer-lasting and increased anti-VEGF activity. However, the company is facing competition from established drugs like Eylea and Lucentis, and their success will depend on their ability to improve their manufacturing process and gain regulatory approval. The potential for TH103 to treat other VEGF-related retinal diseases also presents a promising opportunity for Kalaris. Additionally, the company's strong patent portfolio adds a layer of protection for potential investors.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares